| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 06/06/2001 | EP1104758A1 Acetylene derivatives as anti-inflammatory/analgesic agents |
| 06/06/2001 | EP1104462A2 Bpc-1: a secreted brain specific protein expressed and secreted by prostate and bladder cancer cells |
| 06/06/2001 | EP1104440A1 A g-protein coupled 7tm receptor (axor-1) |
| 06/06/2001 | EP1104421A1 3-(4-amino-5-ethylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1h-pyrazolo 3,4-b]pyridine |
| 06/06/2001 | EP1104410A1 New carboxylic acid derivatives carrying keto side-chains, their production and their use as endothelin-receptor antagonists |
| 06/06/2001 | EP1104408A2 Drug targeting |
| 06/06/2001 | EP1104307A2 Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix |
| 06/06/2001 | CN1297756A Recipe of Chinese medicine for treating nephritis |
| 06/06/2001 | CN1066624C Dry mix formulation for bisphosphonic acids |
| 06/05/2001 | US6242637 Substituted heterocylic compounds, method of preparing them and pharmaceutical compositions in which they are present |
| 06/05/2001 | US6242611 Phenylimidazolidines containing nitrooxy or carbonyloxy groups |
| 06/05/2001 | US6242601 Heterocyclic sulfamides |
| 06/05/2001 | US6242568 Zinc finger protein derivatives and methods therefor |
| 06/05/2001 | US6242497 Use of 6,7-substituted 2-aminotetralines suitable for preparing a pharmaceutical composition for the therapeutic treatment of inflammatory and/or autoimmune pathologies |
| 06/05/2001 | US6242479 Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease |
| 06/05/2001 | US6242449 Treating prostatic hypertrophy, urination disorders associated with prostatic hypertrophy, male pattern alopecia, or acne |
| 06/05/2001 | US6242438 3-Azetidinylalkylpiperidines or -pyrrolidines as tachykinin antagonists |
| 06/05/2001 | US6242434 Treatment and prophylaxis of hyperparathyroidism and hyperproliferative diseases, and in the modulation of the immune and inflammatory responses as well as the treatment of bone depletive disorders. |
| 06/05/2001 | US6242212 Nucleotide sequences which code a protein for the diagnosis, detection and treatment of cancer |
| 06/03/2001 | CA2327385A1 Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents |
| 06/03/2001 | CA2327256A1 Heteroaryl phenyl pyrazole compounds as anti-inflammatory/analgesic agents |
| 05/31/2001 | WO2001038566A2 Screening method for candidate drugs |
| 05/31/2001 | WO2001038486A2 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 05/31/2001 | WO2001038325A1 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 05/31/2001 | WO2001038320A1 Vitamin d analogues |
| 05/31/2001 | WO2001038315A1 Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
| 05/31/2001 | WO2001038314A1 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
| 05/31/2001 | WO2001038313A1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p39 kINASE INHIBITORS |
| 05/31/2001 | WO2001038312A1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS |
| 05/31/2001 | WO2001038311A2 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 05/31/2001 | WO2001038310A1 2-arylquinoline derivatives, preparation and therapeutic use thereof |
| 05/31/2001 | WO2001038305A2 Novel il-8 receptor antagonists |
| 05/31/2001 | WO2001038295A1 Sphingosine derivatives |
| 05/31/2001 | WO2001038293A1 Ethers of o-desmethyl venlafaxine |
| 05/31/2001 | WO2001037868A1 Assays and therapies for latent viral infection |
| 05/31/2001 | WO2001037862A2 A vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias |
| 05/31/2001 | WO2001037857A1 Major intrinsic protein (mip)-like polynucleotides, polypeptides, and antibodies |
| 05/31/2001 | WO2001037848A1 Mixture of pomegranate seed oil and juice products |
| 05/31/2001 | WO2001037837A1 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS |
| 05/31/2001 | WO2001037819A2 Use of indirubine derivatives for making medicines |
| 05/31/2001 | WO2001037808A1 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 05/31/2001 | WO2001037780A2 Urotensin-ii analogs |
| 05/31/2001 | WO2000071140A3 Methods and compositions for modulating immune response and for the treatment of inflammatory disease |
| 05/31/2001 | WO2000047194A9 METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR |
| 05/31/2001 | WO1999064041A9 Multibinding agents that modulate nmda receptors |
| 05/31/2001 | US20010002397 24-Hydroxyvitamin D, analogs and uses thereof |
| 05/31/2001 | CA2706113A1 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 05/31/2001 | CA2395049A1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 05/31/2001 | CA2392456A1 Assays and therapies for latent viral infection |
| 05/31/2001 | CA2392366A1 Major intrinsic protein (mip)-like polynucleotides, polypeptides, and antibodies |
| 05/31/2001 | CA2392225A1 Novel il-8 receptor antagonists |
| 05/31/2001 | CA2392149A1 2-arylquinoline derivatives, preparation and therapeutic use thereof |
| 05/31/2001 | CA2391288A1 Ethers of o-desmethyl venlafaxine |
| 05/31/2001 | CA2390923A1 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 05/31/2001 | CA2390465A1 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 05/31/2001 | CA2389537A1 Mixture of pomegranate seed oil and juice products |
| 05/31/2001 | CA2387591A1 Use of indirubine derivatives for making medicines |
| 05/31/2001 | CA2386955A1 Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
| 05/30/2001 | EP1103553A2 Substituted heterocyclic derivatives |
| 05/30/2001 | EP1103544A2 Piperidine derivatives and antiplatelet agents containing the same |
| 05/30/2001 | EP1103272A2 Modulation of TGF-beta by proteolytic enzymes |
| 05/30/2001 | EP1102842A2 Antisense oligonucleotides for the inhibition of vegf expression |
| 05/30/2001 | EP1102838A2 A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 05/30/2001 | EP1102789A1 Monocyclic compounds having nk-2 antagonist action and compositions containing them |
| 05/30/2001 | EP1102754A1 Imidazoles and related compounds as alpha-1a agonists |
| 05/30/2001 | EP1102597A1 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht 4 receptors |
| 05/30/2001 | EP1102593A1 Prostate formula |
| 05/30/2001 | EP1102584A2 Antioxidant, antiproliferous composition, comprising a carnitine and a carotenoid |
| 05/30/2001 | EP0914334B1 Process and intermediates for the synthesis of lhrh antagonists |
| 05/30/2001 | EP0665834B1 Quinolone and acridinone derivatives for the treatment of urinary incontinence |
| 05/30/2001 | CN1297432A Substd. amides, their production and their use |
| 05/30/2001 | CN1297354A Dipeptide caspase inhibitors and use thereof |
| 05/30/2001 | CN1066441C Isooxazolyl phenyl sulfonamide derivs. and use of same in preparing endothelin antagonists |
| 05/29/2001 | US6239172 Mixture of angiogenic growth factor and l-arginine; brain and cardiovascular disorders |
| 05/29/2001 | US6239147 To treat cns, gastrointestinal and other disorders. substance p antagonists having improved activity and fewer side effects, treatment of emesis induced by antineoplastic agents, isochroman ring |
| 05/29/2001 | US6238900 Nucleotide sequence coding enzymatic polypeptide; for the prevention of bacterial infections; bactericides |
| 05/29/2001 | CA2195923C Azetidines |
| 05/25/2001 | WO2001036684A2 Mammalian toxicological response markers |
| 05/25/2001 | WO2001036642A1 HUMAN MONOCLONAL ANTIBODIES AGAINST TGF-βII RECEPTOR AND MEDICINAL USE THEREOF |
| 05/25/2001 | WO2001036610A1 Human enzymes of the metalloprotease family |
| 05/25/2001 | WO2001036605A2 2786, a human aminopeptidase |
| 05/25/2001 | WO2001036451A1 Vitamin e derivatives |
| 05/25/2001 | WO2001036422A1 Tricyclic dihydropyrimidine potassium channel openers |
| 05/25/2001 | WO2001036416A1 Novel thiazolidinedione derivatives as antidiabetic agents |
| 05/25/2001 | WO2001036403A1 Urea derivatives as anti-inflammatory agents |
| 05/25/2001 | WO2001036395A1 Triazoles as farnesyl transferase inhibitors |
| 05/25/2001 | WO2001036375A1 Aminoalcohol derivatives useful for the treatment of gastrointestinal disorders |
| 05/25/2001 | WO2001036360A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| 05/25/2001 | WO2001035999A1 Stable amorphous amifostine composition, and preparation thereof |
| 05/25/2001 | WO2001035961A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/25/2001 | WO2001035960A1 Use of substituted 4-(quinolin 2-yl-methoxy)phenyl-acetic acid derivatives for the treatment of diseases |
| 05/25/2001 | WO2001035957A1 Stable salts of novel derivatives of 3,3-diphenylpropylamines |
| 05/25/2001 | WO2001035936A2 Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and -cyanamides for the treatment of diseases |
| 05/25/2001 | CA2392076A1 Human enzymes of the metalloprotease family |
| 05/25/2001 | CA2391913A1 Novel thiazolidinedione derivatives as antidiabetic agents |
| 05/25/2001 | CA2391418A1 Stable amorphous amifostine composition, and preparation thereof |
| 05/25/2001 | CA2391291A1 Tricyclic dihydropyrimidine potassium channel openers |
| 05/25/2001 | CA2389862A1 Human monoclonal antibody against tgf-.beta.ii receptor and medicinal use thereof |
| 05/25/2001 | CA2389289A1 Mammalian toxicological response markers |
| 05/23/2001 | EP1101757A1 Heterocyclic compounds as tachykinin receptor antagonists |